BioSpace News Archive

Rapid Micro Biosystems, Inc., an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced that the Company will participate in the following investor conferences.

Tenaya Therapeutics, Inc. announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.53, which was the closing price on February 26, 2024, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock.

Tevogen Bio Holdings – Tevogen Chief Information Officer and Head of company’s Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken strides to emphasize the importance of proactive talent development for biopharmaceutical sector to allow rapid adoption of artificial intelligence.

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.

PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.

Accuray Incorporated announced its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.

QIAGEN announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries.

Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.

Veru Inc. announced that it received a delinquency notification letter from the Listing Qualifications staff of the Nasdaq Stock Market LLC on February 21, 2024 due to the Company’s non-compliance with Nasdaq Listing Rule 5250 as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023.